Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olutasidenib Post-transplant Maintenance Therapy for IDH1-mutated Myeloid Malignancies
NCT06668584Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olutasidenib in myeloid malignancies, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and Adverse Events at 1 year. Started Dec 2024; status: recruiting.
02
Drugs
olutasidenib
03
Conditions
myeloid malignancies
Beyond the preview
Go deeper on NCT06668584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06668584.